Market reactionShares rose 14% on Nov 3.
Calidi Biotherapeutics develops virus-based cancer therapies; its lead, CLD-401 for lung and head and neck cancer, has not yet entered human trials.
Calidi's case rests on bringing CLD-401, a systemic virus delivering an immune-activating payload within tumors, into human trials. Positive pre-IND feedback supports its first-patient target of Q1 2027. New animal and T-cell engager findings broaden RedTail's potential, but financing remains the constraint: cash was $4.1 million at June 30, 2026, and the company reported going-concern doubt. A subsequent offering targeted approximately $1.2 million gross. The NYSE American equity deficiency adds pressure to secure capital.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: First patient dosed with CLD-401
Does Calidi secure financing and begin first-in-human CLD-401 dosing on its stated schedule?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
RedTail animal findings broaden potential; financing still constrains CLD-401's clinical path
Oncolytic viral platform racing a going-concern clock: survival to first-in-human dosing is the only question that matters
Oncolytic virus platform racing an ~$4M cash position toward first-in-human; survival to Phase 1 dosing is the only question that matters now
CLD-401's first-in-human readout will determine whether Calidi's oncolytic stem-cell platform can generate clinical signals in solid tumors before cash runs out
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.